English 
Japanese 
May 25, 2026
Cardiac Safety Evaluation Results from Phase 1 Clinical Studies of E7386, Jointly Created by PRISM BioLab and Eisai, to Be Shared by Eisai at the ASCO Annual Meeting
PRISM BioLab today announced that the abstract titled "Leveraging E7386 phase 1 trials for cardiac safety:...
Read More
May 22, 2026
Notice of Participation in Radio NIKKEI Japan Tour
PRISM BioLab announces that our President and CEO, Dai Takehara, will participate as a speaker at...
Read More
May 18, 2026
Notice of Expiration of the Research and License Agreement with Boehringer Ingelheim International GmbH
PRISM BioLab announces that the research and license agreement between PRISM BioLab and Boehringer Ingelheim International...
Read More
May 11, 2026
Notice of Allowance for PepMetics® Technology Library Compounds Patent in the United States
PRISM BioLab announces that we have received a Notice of Allowance for a patent on PepMetics®...
Read More
April 7, 2026
Eisai to Present Preclinical Research Results of E7386, Co-Created with PRISM BioLab, at the AACR Annual Meeting 2026
PRISM BioLab announces that Eisai Co., Ltd. will present preclinical research results for E7386, co-created by...
Read More
March 13, 2026
PRISM BioLab and Receptor.AI Announce Drug Discovery Collaboration Agreement
PRISM BioLab and Receptor.AI today announced that they have entered into a drug discovery collaboration agreement...
Read More
January 22, 2026
Phase 1 clinical research results of E7386, Jointly Created by PRISMBioLab and Eisai, Published in ESMO OPEN
PRISM BioLab announces that a paper reporting the results of a domestic Phase I clinical trial...
Read More
January 20, 2026
Notice of Tokyo Office Relocation
We would like to inform you that PRISM BioLab will relocate our Tokyo office to the...
Read More
December 18, 2025
PRISM BioLab and Talus Bioscience Announce Joint Research Agreement
PRISM BioLab and Talus Bioscience, Inc. are pleased to announce that we have entered into a...
Read More
November 28, 2025
PRISM BioLab Announces Patent Grant for Novel Bicyclic PepMetics® Compounds
PRISM BioLab was granted a new patent covering a novel class of bicyclic PepMetics® compounds on...
Read More